KarXT for schizophrenia-effectiveness and value: A summary from the Institute for Clinical and Economic Review's New England Comparative Effectiveness Public Advisory Council.

Subjects

Subjects :

Humans
Cost-Benefit Analysis
New England
Advisory Committees
United States
Schizophrenia economics
Schizophrenia drug therapy
Antipsychotic Agents economics
Antipsychotic Agents therapeutic use
Comparative Effectiveness Research

Details

Language :

English

ISSN :

2376-1032

Volume :

30

Issue :

6

Database :

MEDLINE

Journal :

Journal of managed care & specialty pharmacy

Publication Type :

Academic Journal

Accession number :

38824622

Full Text :

https://doi.org/10.18553/jmcp.2024.30.6.624